Genetic variation drives cancer cell adaptation to ECM stiffness.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
24 Sep 2024
Historique:
medline: 20 9 2024
pubmed: 20 9 2024
entrez: 20 9 2024
Statut: ppublish

Résumé

The progression of many solid tumors is accompanied by temporal and spatial changes in the stiffness of the extracellular matrix (ECM). Cancer cells adapt to soft and stiff ECM through mechanisms that are not fully understood. It is well known that there is significant genetic heterogeneity from cell to cell in tumors, but how ECM stiffness as a parameter might interact with that genetic variation is not known. Here, we employed experimental evolution to study the response of genetically variable and clonal populations of tumor cells to variable ECM stiffness. Proliferation rates of genetically variable populations cultured on soft ECM increased over a period of several weeks, whereas clonal populations did not evolve. Tracking of DNA barcoded cell lineages revealed that soft ECM consistently selected for the same few variants. These data provide evidence that ECM stiffness exerts natural selection on genetically variable tumor populations. Soft-selected cells were highly migratory, with enriched oncogenic signatures and unusual behaviors such as spreading and traction force generation on ECMs with stiffness as low as 1 kPa. Rho-regulated cell spreading was found to be the directly selected trait, with yes-associated protein 1 translocation to the nucleus mediating fitness on soft ECM. Overall, these data show that genetic variation can drive cancer cell adaptation to ECM stiffness.

Identifiants

pubmed: 39302966
doi: 10.1073/pnas.2403062121
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2403062121

Subventions

Organisme : NCI NIH HHS
ID : U01 CA225566
Pays : United States
Organisme : Cancer Prevention and Research Institute of Texas (CPRIT)
ID : RR200043
Organisme : NCI NIH HHS
ID : U01 CA225566
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA253540
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA226258
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA255536
Pays : United States

Déclaration de conflit d'intérêts

Competing interests statement:J.D.L. serves as a consultant for AstraZeneca.

Auteurs

Ting-Ching Wang (TC)

Artie McFerrin Department of Chemical Engineering, Texas A&M University, College Station, TX 77843.

Suchitaa Sawhney (S)

Department of Biomedical Engineering, Texas A&M University, College Station, TX 77843.

Daylin Morgan (D)

Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX 78712.

Richard L Bennett (RL)

Division of Hematology and Oncology, University of Florida Health Cancer Center, Gainesville, FL 32610.

Richa Rashmi (R)

Department of Cell Biology and Genetics, Texas A&M University, Bryan, TX 77807.

Marcos R Estecio (MR)

Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.

Amy Brock (A)

Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX 78712.

Irtisha Singh (I)

Department of Biomedical Engineering, Texas A&M University, College Station, TX 77843.
Department of Cell Biology and Genetics, Texas A&M University, Bryan, TX 77807.

Charles F Baer (CF)

Department of Biology, University of Florida, Gainesville, FL 32611.

Jonathan D Licht (JD)

Division of Hematology and Oncology, University of Florida Health Cancer Center, Gainesville, FL 32610.

Tanmay P Lele (TP)

Artie McFerrin Department of Chemical Engineering, Texas A&M University, College Station, TX 77843.
Department of Biomedical Engineering, Texas A&M University, College Station, TX 77843.
Department of Translational Medical Sciences, Texas A&M University, Houston, TX 77030.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH